Case Report: Home-based Management of Severe COVID-19 with Low-dose TofacitinibArticles Published on 2021-12-042022-10-28 Journal: The American Journal of Tropical Medicine and Hygi [Category] COVID-19, SARS, [키워드] addition affected Baricitinib COVID-19 COVID-19 pandemic Cytokine storm extreme feasibility glucocorticoid healthcare hospital Human hyperinflammatory state Hypoxemia immunomodulatory drug India inhibitor Janus kinase low-dose medications monotherapy Mortality oxygen Patient patients with COVID-19 Rapid reduction in resource severe COVID-19 systemic the disease therapy Tocilizumab Tofacitinib treated [DOI] 10.4269/ajtmh.21-0737 PMC 바로가기 [Article Type] Articles
Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for HypertensionObservational Study Published on 2021-12-012022-10-05 Journal: Journal of General Internal Medicine [Category] SARS, 임상, [키워드] 95% CI 95% confidence interval ACEi ACEIs Admission Analysis angiotensin receptor blocker Angiotensin receptor blockers Angiotensin-converting enzyme angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitors ARB ARBs beneficiary blocker case-control study CCB CCBs Control COVID-19 death determine diuretics duration of hospitalization female Hospitalization Hospitalized hypertension ICU ICU admission increased risk Intensive intensive care interquartile range Invasive mechanical ventilation mechanical ventilation median age Medicare monotherapy Odds ratio outcome receptor reduction in residual confounding risk System the median treated Treatment [DOI] 10.1007/s11606-021-07155-z PMC 바로가기 [Article Type] Observational Study
Data mining methodology for response to hypertension symptomology—application to COVID-19-related pharmacovigilance고혈압 증상에 대한 데이터 마이닝 방법론 - COVID-19 관련 약물 감시에 적용Research Article Published on 2021-11-232022-09-10 Journal: eLife [Category] MERS, SARS, 치료기술, [키워드] acting acute respiratory illness ADE ADEs Adverse Affect affecting angiotensin Antihypertensive drug antihypertensive drugs Antithrombotic artificial intelligence association beraprost blockers blood pressure bosentan build calcium calcium channel calcium channel blockers candesartan Cluster Combination confounding factor confounding factors coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19-related pharmacovigilance data-driven methodology demographics disease Disease prevalence distribution doxazosin drug drugs effective endothelin receptor antagonist Endothelin receptor antagonists Epoprostenol evaluated exhibited Factor FDA FDA ADE database feature filtered Friedman test funding geometric geometric mean group had no hidden high risk highest hypertension Hypothesis incidence limit macitentan medication medications meta-analyses Meta-analysis methodology monotherapy Nifedipine None operator outcome Patient patients pharmacovigilance Potential potential therapy profile Pulmonary function pulmonary symptomology Quantitative randomized clinical trials Renin renin-angiotensin system reported Reporting respiratory Respiratory illness retrieved rilmenidine selected drug selected drugs selexipag shown Side effect significant difference significant differences significantly higher Sildenafil Stage Tadalafil Therapeutics therapy [DOI] 10.7554/eLife.70734 PMC 바로가기 [Article Type] Research Article
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors종양 괴사 인자-α 억제제를 투여받는 mRNA 백신 접종 개인의 혈청에서 SARS-CoV-2 B.1.617.2 델타 바이러스에 대한 항체 활성 감소Clinical and Translational Article Published on 2021-11-182022-09-14 Journal: Med (New York, N.Y.) [Category] SARS, 변종, 진단, 치료법, [키워드] Abstract acute respiratory syndrome administration Alpha Analysis antibody Antibody Response B.1.351 B.1.617.2 BNT162b2 BNT162b2 mRNA vaccine center chronic inflammatory disease Cohort Context coronavirus coronavirus disease COVID-19 dose evaluated Fc effector functions finding function capacity funding immunization Immunocompromised immunocompromised individuals immunogenic Immunosuppression immunosuppressive immunosuppressive drug in healthy individuals individual individuals inhibitor inhibitors Innovation less longitudinal lowest monoclonal antibodies monotherapy mRNA vaccine Necrosis neutralization Neutralizing neutralizing antibody Neutralizing antibody titer Neutralizing titer neutralizing titers NIAID Pfizer populations Prevent Prophylaxis protective immunity receiving recipients reduced reductions in required response SARS-CoV-2 SARS-COV-2 infection serum serum antibody serum antibody response Serum neutralizing antibody severe disease strain supported susceptible tested Therapies therapy threshold TNF inhibitors TNF-α treated tumor necrosis factor-α vaccination Vaccine vaccine dose variant variants variants of concern virus [DOI] 10.1016/j.medj.2021.11.004 PMC 바로가기 [Article Type] Clinical and Translational Article
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort studyArticles Published on 2021-11-092022-10-29 Journal: The Lancet Rheumatology [Category] COVID-19, [키워드] 95% CI Administered All participant Alpha Antibody Response B.1.1.7 B.1.617.2 BNT162b2 Cell cellular cellular immunity cellular response Cohort cohort study college Control COVID-19 vaccine defined Delta variants demonstrated detectable eight England evaluated extended interval finding foundation functional funding General population group healthy control healthy controls Humoral immunity IL-17 IL-2 IL-21 IL-23 immune response Immune-mediated inflammatory disease immunogenicity Immunosuppressant Immunosuppression individual inhibitor inhibitors interferon-γ IQR King London longitudinal cohort study magnitude male median median age methotrexate monotherapy Necrosis neutralising antibody Neutralising antibody responses neutralising antibody titre NHS NIHR no difference of BNT162b2 participant Patient Pfizer-BioNTech Primary outcome producing proportion psoriasis receiving recruited regimen robust SARS-CoV-2 variants second dose second vaccination single dose spike glycoprotein Spike-specific antibody spike-specific IgG spike-specific T-cell response study population T-cell Response the SARS-CoV-2 Thoma titre TNF Trust vaccination vaccine dose vaccine doses Volunteer white wild-type [DOI] 10.1016/S2665-9913(21)00333-7 PMC 바로가기 [Article Type] Articles
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD RegistrySECURE-IBD 레지스트리에서 성인 IBD 환자의 COVID-19 결과에 대한 베돌리주맙의 영향Article Published on 2021-11-082022-09-12 Journal: Journal of Crohn's & colitis [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval adjusted odds ratio anti-TNF appear bowel Care comparable coronavirus disease Coronavirus disease 2019 covariates COVID-19 COVID-19 hospitalization Crohn’s disease determine Exploratory analysis Gastrointestinal symptom Hospitalization IBD Impact Inflammatory bowel disease International mechanical ventilation medication monotherapy multivariable analysis Necrosis outcome outcomes Patient patients patients with COVID-19 registry Safe severe COVID-19 Therapies therapy ulcerative ulcerative colitis vedolizumab [DOI] 10.1093/ecco-jcc/jjab071 PMC 바로가기 [Article Type] Article
513. Use of Antimicrobial Stewardship Program in Operationalizing Monoclonal Antibody Therapy in SARS-CoV-2 InfectionPoster Abstracts Published on 2021-11-042022-10-29 Journal: Open Forum Infectious Diseases [Category] COVID-19, [키워드] acute respiratory syndrome adverse event Algorithm antimicrobial approach approval approved ASP benefit Cohort collected complications coronavirus coronavirus disease COVID-19 death decrease demographics Dual therapy effort eligibility eligible patient Emergency use authorization EUA hospital Hospitalization Infection male monoclonal antibody monotherapy Nurse occurred online tool outcome pandemic Patient patients required hospitalization physician Physicians Program provided receive receiving Regulatory reported Result SARS-CoV-2 SARS-COV-2 infection screened Support therapy treated patients white [DOI] 10.1093/ofid/ofab466.712 PMC 바로가기 [Article Type] Poster Abstracts
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19면역매개염증질환 및 코로나19 환자에서 종양괴사인자억제제와 입원 또는 사망 위험 간의 연관성Research Published on 2021-10-182022-09-12 Journal: JAMA Network Open [Category] MERS, SARS, 진단, [키워드] 6-mercaptopurine 95% CI accounted accounting Adult patients age Analysis Arthritis association azathioprine category Clinical characteristics cohort study Combination conducted correlations country COVID-19 COVID-19 diagnosis Crohn disease data entry death demographic and clinical characteristics diagnose Diagnosis died Europe excluded exposure Factor female finding higher odd higher odds Hospitalization Hospitalized immune pathway Immune-mediated inflammatory disease Immune-mediated inflammatory diseases immunomodulatory Importance individual Inflammatory arthritis Inflammatory bowel disease Inflammatory diseases inhibitor International Janus kinase Kinase inhibitor lower risk measure methotrexate monotherapy multivariable logistic regression Necrosis objective Odds ratio outcome pandemic participant Patient Point psoriasis receipt receiving reference treatment Relevance reported reporting bias Result Rheumatic diseases rheumatoid arthritis risk Sensitivity analyses sensitivity analysis setting significantly higher Support Symptom the mean therapy TNF treatment regimen Tumor tumor necrosis tumor necrosis factor [DOI] 10.1001/jamanetworkopen.2021.29639 PMC 바로가기 [Article Type] Research
Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysisResearch Article Published on 2021-10-162022-10-31 Journal: Cancer Medicine [Category] COVID-19, MERS, [키워드] addition Analysis benefit collaboration collected comparable COVID‐19 COVID‐19 deficiency demonstrated Denmark effective Efficacy Efficacy and safety evaluate Evidence HCC hepatocellular Hepatocellular carcinoma hyperthermia hyperthermia ablation incidence indicated large sample limitation Liver damage material meta‐analysis monotherapy no significant difference Patient patients performed produced reduced regimen Research Result Safe SARS‐CoV‐2 significantly surgical resection survival systematic review TACE the patient therapy Toxicity transarterial chemoembolization was performed [DOI] 10.1002/cam4.4350 PMC 바로가기 [Article Type] Research Article
Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemicResearch Article Published on 2021-10-072022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] 95% CI 95% confidence interval affected agonist all-cause mortality Analysis androgen base COVID-19 COVID-19 mortality COVID-19 pandemic death Deprivation died Evidence exposure to facilitate GnRH higher risk highest IMPROVE incidence of COVID-19 infection rate initial main analysis men monotherapy Mortality mortality rate ratio multivariable National outcome population-based cohort prevalent Prostate cancer reduce Region respiratory epithelial cells Result Support the SARS-CoV-2 virus therapy was increased women [DOI] 10.1371/journal.pone.0255966 PMC 바로가기 [Article Type] Research Article